Neukio Biotherapeutics, a Chinese company committed to developing cell therapy products, raised $50M in Series A-1 funding.
The round was led by CD Capital, with participation from Alwin Capital, Surplus Capital, Lilly Asia Ventures, Sherpa Healthcare Partners and IDG Capital.
The company, founded at the Simbay Park in Shanghai Pilot Free Trade Zone (China) in June 2021, intends to use the funds to accelerate the preclinical and clinical validation of induced pluripotent stem cell (iPSC)-derived off-the-shelf CAR-NK cell therapy products, and support team recruitment and expansion.
Led by CEO Dr. Richard Liqun Wang, Neukio Biotherapeutics is a biotherapeutic company focusing on the development and commercialization of immune cell therapy. Its management team has established an iPSC-CAR-NK-based pipeline development strategy, aiming to launch allogenic off-the-shelf cell therapy products that can be produced in scale for treating solid tumors. The company focuses on both in-house R&D to provide valuable clinical solutions for cancer patients worldwide.
Since its establishment just over one year ago, Neukio has made remarkable progress in talent recruitment, facility construction, R&D pipeline advancement and quality management system establishment, exceeding all expectations.